These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37796980)

  • 1. The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands.
    Ouaddouh C; Duijster JW; Lieber T; van Hunsel FPAM
    Expert Opin Drug Saf; 2024 Mar; 23(3):323-331. PubMed ID: 37796980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
    Duijster JW; Lieber T; Pacelli S; Van Balveren L; Ruijs LS; Raethke M; Kant A; Van Hunsel F
    Front Immunol; 2023; 14():1078736. PubMed ID: 36793715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands.
    Kant A; Jansen J; van Balveren L; van Hunsel F
    Drug Saf; 2022 Apr; 45(4):319-331. PubMed ID: 35314943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.
    Spinelli FR; Favalli EG; Garufi C; Cornalba M; Colafrancesco S; Conti F; Caporali R
    Arthritis Res Ther; 2022 Jan; 24(1):21. PubMed ID: 35016701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
    Deng L; Glover C; Dymock M; Pillsbury A; Marsh JA; Quinn HE; Leeb A; Cashman P; Snelling TL; Wood N; Macartney K
    Med J Aust; 2022 Aug; 217(4):195-202. PubMed ID: 35781813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Side effects after COVID-19 vaccinations among residents of Poland.
    Andrzejczak-Grządko S; Czudy Z; Donderska M
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.
    Rider LG; Parks CG; Wilkerson J; Schiffenbauer AI; Kwok RK; Noroozi Farhadi P; Nazir S; Ritter R; Sirotich E; Kennedy K; Larche MJ; Levine M; Sattui SE; Liew JW; Harrison CO; Moni TT; Miller AK; Putman M; Hausmann J; Simard JF; Sparks JA; Miller FW;
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI143-SI150. PubMed ID: 35460240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to receive a vaccine is influenced by adverse events following immunisation experienced by others.
    Christou-Ergos M; Wiley KE; Leask J
    Vaccine; 2023 Jan; 41(1):246-250. PubMed ID: 36446655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study.
    Mascolo A; di Mauro G; Fraenza F; Gaio M; Zinzi A; Pentella C; Rossi F; Capuano A; Sportiello L
    Front Immunol; 2022; 13():965171. PubMed ID: 36263025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands.
    van der Boor SC; Schmitz-de Vries ETJ; Smits D; Scholl JHG; Rolfes L; van Hunsel F
    Vaccine; 2023 Jun; 41(29):4319-4326. PubMed ID: 37286408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.
    Seirafianpour F; Pourriyahi H; Gholizadeh Mesgarha M; Pour Mohammad A; Shaka Z; Goodarzi A
    Dermatol Ther; 2022 Jun; 35(6):e15461. PubMed ID: 35316551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Self-reported maternal adverse events of covid-19 vaccination during pregnancy].
    Woestenberg PJ; Litjens CHC; Vissers LCM; Kant A; Berrens M; Vorstenbosch S
    Ned Tijdschr Geneeskd; 2022 Dec; 166():. PubMed ID: 36633023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between COVID-19 vaccines and development of chronic morbidities: a cross-sectional study in the Jordanian population.
    Al-Hawamdeh MI; Abu-Huwaij R; Astiti TA; Al-Debe'e AK; Abazeed OJ; Raees MA
    Curr Med Res Opin; 2024 Mar; 40(3):537-543. PubMed ID: 38193825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disproportionality analysis of adverse neurological and psychiatric reactions with the ChAdOx1 (Oxford-AstraZeneca) and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccines in the United Kingdom.
    Otero-Losada M; Petrovsky N; Alami A; Crispo JA; Mattison D; Capani F; Goetz C; Krewski D; Perez-Lloret S
    Expert Opin Drug Saf; 2023 Apr; 22(4):343-349. PubMed ID: 36043937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.
    Kim S; Bea S; Choe SA; Choi NK; Shin JY
    Eur J Clin Pharmacol; 2024 Mar; 80(3):445-453. PubMed ID: 38212538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menstrual abnormalities after COVID-19 vaccination in the Netherlands: A description of spontaneous and longitudinal patient-reported data.
    Duijster JW; Schoep ME; Nieboer TE; Jajou R; Kant A; van Hunsel F
    Br J Clin Pharmacol; 2023 Oct; 89(10):3126-3138. PubMed ID: 37222170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021.
    Tran VN; Nguyen HA; Le TTA; Truong TT; Nguyen PT; Nguyen TTH
    Vaccine; 2021 Oct; 39(44):6485-6491. PubMed ID: 34607748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.